The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of capecitabine, carboplatin, and bevacizumab for metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma.
Pamela L. Kunz
Research Funding - Genentech/Roche; Merrimack Pharmaceuticals
Prachi Nandoskar
No relevant relationships to disclose
Michael Zach Koontz
No relevant relationships to disclose
Hanlee Ji
No relevant relationships to disclose
James M. Ford
Research Funding - Genentech/Roche
Raymond R. Balise
No relevant relationships to disclose
Aya Kamaya
No relevant relationships to disclose
Daniel Rubin
No relevant relationships to disclose
George A. Fisher
No relevant relationships to disclose